I was born in Bulawayo, Zimbabwe and studied medicine at the University of Cape Town in South Africa. My technical field of expertise is Drug Development through all phases of development after Discovery including Manufacturing of Bulk Drug, Formulation, Toxicology and Phase 1 through 4. It also includes Clinical, Regulatory, Biometrics and Data Management. I have particular experience in large scale clinical trials in the area of cardiovascular risk management and in maximizing market potential of drugs in development. I have specific experience in clinical endpoint studies, advanced surrogates such as IVUS, EBCT, Carotid ultrasound and Holter monitoring and in combination drug development. I am Chief Medical Officer of Cerenis Therapeutics, located in Toulouse, France. Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of the next generation HDL therapies. From 2002 until 2007, I was Executive Vice President of Research & Development and Chief Medical Officer at AtheroGenics. AtheroGenics was focused on new drug development in the areas of Cardiology, Rheumatology and Pulmonology. Prior to that I was Vice President and Medical Therapeutic Head of the Cardiovascular & Metabolic Group at Pfizer Inc. In this position, I was responsible for the global development of Norvasc, Lipitor, Tikosyn, Accupril, the Dual Therapy Compound, Glucotrol XL and Exubera (Inhaled Insulin). I directed the Pfizer Atherosclerosis Research Program, including the large, multicenter, Phase III PREVENT study. I have played a key role on many international studies such as TNT, CAMELOT/NORMALISE, SAGE, MIRACL, BELLES, REVERSAL and SPARCL.